Cell-in-drop genotyping detects megabase-scale loss of heterozygosity as a quantitative marker for CRISPR-Cas9 on-target toxicity
- 1Memorial Sloan Kettering Cancer Center
Abstract
Targeted DNA double strand breaks catalyzed by CRISPR-Cas9 have been demonstrated to cause megabase-scale segmental deletions and whole chromosome losses in a wide variety of mouse and human cell lines. This raises safety concerns for CRISPR-Cas9 based therapeutics and highlights the need for scalable methods to assess its on-target genotoxicity in clinical contexts. In this report, we present cell-in-drop genotyping, as a high throughput approach that combines single cell encapsulation with droplet-based PCR genotyping of endogenous polymorphisms to detect loss of heterozygosity (LOH) at a targeted chromosome without any genome manipulation. With this approach, we detected megabase scale LOH induced by Cas9 DSBs, mostly frequently by segmental loss. This approach also detected LOH from loss of a critical DNA repair factor, BLM helicase, and LOH induced by other genotoxic conditions, in particular, the chemotherapeutic drugs Paclitaxel and Mitomycin C, which were demonstrated to induce LOH by different mechanisms. A modified version of the assay also captured rare local short range LOH arising from DSB-induced interhomologue recombination. Because it requires no genome manipulation, cell-in-drop genotyping offers a practical, scalable tool for evaluating genotoxic risk of CRISPR-Cas9 and other agents in research and clinical development.
Related
- Creation of genomic chimeras via megabase scale genome expansion
- The First Case of Digenic MODY Diabetes Involving Compound Heterozygosity of Three Variants in the PDX1 and HNF1B Genes
- Cell-envelope conduits enable transfer of megabase-sized double-stranded DNA between cells of the nosocomial pathogen Acinetobacter baumannii
- Identification and genetic characterization of megabase-scale plasmids of Enterobacteriaceae
- A giant virus with a 4-megabase genome and a vastly expanded repeatome.
BibTeX
@misc{medhi2026cellindrop,
title = {{Cell-in-drop genotyping detects megabase-scale loss of heterozygosity as a quantitative marker for CRISPR-Cas9 on-target toxicity}},
author = {D. Medhi and L. Mazutis and M. Jasin},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.30.763197},
url = {https://www.biorxiv.org/content/10.64898/2026.10.30.763197v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Cell-in-drop genotyping detects megabase-scale loss of heterozygosity as a quantitative marker for CRISPR-Cas9 on-target toxicity
AU - D. Medhi
AU - L. Mazutis
AU - M. Jasin
PY - 2026
DA - 2026/10/30
PB - bioRxiv
DO - 10.64898/2026.10.30.763197
UR - https://www.biorxiv.org/content/10.64898/2026.10.30.763197v1
AB - Targeted DNA double strand breaks catalyzed by CRISPR-Cas9 have been demonstrated to cause megabase-scale segmental deletions and whole chromosome losses in a wide variety of mouse and human cell lines. This raises safety concerns for CRISPR-Cas9 based therapeutics and highlights the need for scalable methods to assess its on-target genotoxicity in clinical contexts. In this report, we present cell-in-drop genotyping, as a high throughput approach that combines single cell encapsulation with droplet-based PCR genotyping of endogenous polymorphisms to detect loss of heterozygosity (LOH) at a targeted chromosome without any genome manipulation. With this approach, we detected megabase scale LOH induced by Cas9 DSBs, mostly frequently by segmental loss. This approach also detected LOH from loss of a critical DNA repair factor, BLM helicase, and LOH induced by other genotoxic conditions, in particular, the chemotherapeutic drugs Paclitaxel and Mitomycin C, which were demonstrated to induce LOH by different mechanisms. A modified version of the assay also captured rare local short range LOH arising from DSB-induced interhomologue recombination. Because it requires no genome manipulation, cell-in-drop genotyping offers a practical, scalable tool for evaluating genotoxic risk of CRISPR-Cas9 and other agents in research and clinical development.
ER -